Herminder Boparai
Optometrist · Bellevue, WANPI 1639190150
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $93,265 of the $131,215 with a category attached, or 71.1%. Mallinckrodt Hospital Products Inc. accounts for 74.7% of it on its own, with 32 other manufacturers making up the rest. Among optometrist clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 582 payments — averaging $225.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$98K
- Bausch & Lomb Americas Inc.$26K
- Alcon$2K
- Johnson & Johnson Vision Care, Inc.$1K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$737
- Sun Pharmaceutical Industries Inc.$498
- plus $3K from 27 others
What the payments were for
- Consulting fees$1,0001%
- Speaking & faculty fees$93,26571%
- Travel & lodging$20,14515%
- Food & beverage$16,74813%
- Gifts$410%
- Entertainment$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 246 | $97,992 |
| Bausch & Lomb Americas Inc. | 100 | $25,682 |
| Alcon | 32 | $1,679 |
| Johnson & Johnson Vision Care, Inc. | 36 | $1,307 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 31 | $737 |
| Sun Pharmaceutical Industries Inc. | 21 | $498 |
| AbbVie(2 entities) | 25 | $445 |
| Dompe US, Inc. | 12 | $443 |
| Amgen(2 entities) | 9 | $432 |
| Astellas Pharma US Inc | 2 | $225 |
| Novartis | 13 | $221 |
| Lumenis BE Inc | 1 | $212 |
| Aerie Pharmaceuticals, Inc. | 6 | $185 |
| Maculogix, Inc. | 3 | $184 |
| Tarsus Pharmaceuticals, Inc. | 6 | $169 |
| Coopervision Inc. | 5 | $89 |
| Biotissue Holdings Inc. | 3 | $75 |
| Optos, Inc. | 3 | $72 |
| Kala Pharmaceuticals, Inc. | 4 | $67 |
| Glaukos Corporation | 4 | $65 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $62 |
| Thea Pharma Inc. | 3 | $56 |
| ANI Pharmaceuticals, Inc. | 2 | $51 |
| Oyster Point Pharma, Inc. | 2 | $49 |
| Mallinckrodt Enterprises LLC | 2 | $38 |
| Genentech USA, Inc. | 2 | $30 |
| Shire North American Group Inc | 1 | $27 |
| Akorn, Inc. | 1 | $24 |
| LKC Technologies, Inc. | 1 | $24 |
| Visioneering Technologies, Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Akorn Operating Company LLC | 1 | $19 |
| Sight Sciences, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$93,354
- MIEBO$22,817
- XIIDRA$22,260
- BLINK NUTRITEARS$500
- Acuvue$474
- TEPEZZA$275
- TRYPTYR$256
- LOTEMAX SM$251
- BIOTRUE ONE DAY$250
- optilight$212
- ILUX$210
- ORA$170
- DAILIES$133
- Precision 1$133
- BIOTRUE$125
- ULTRA$125
- Oxervate$125
- INFUSE$123
- Rocklatan$114
- Rhopressa$114
How this compares
$131,215 in reported general payments places this provider in the 95th percentile of 1,267 optometrist providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 61 | $60,997 |
| MieboPerfluorohexyloctane/Pf | 64 | $48,154 |
| XiidraLifitegrast | 19 | $16,448 |
| VyzultaLatanoprostene Bunod | 28 | $15,188 |
| LumiganBimatoprost | 19 | $12,001 |
| Latanoprost | 170 | $2,453 |
| Brinzolamide | 21 | $2,445 |
| CombiganBrimonidine Tartrate/Timolol | 12 | $2,424 |
| Brimonidine Tartrate | 13 | $1,275 |
| Timolol Maleate | 42 | $616 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 16 | $431 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 33 | $326 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta | $25,682 | $79,789111 claims |
| AbbVieRestasis, Lumigan, Combigan | $445 | $75,42292 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,267 optometrist providers in Washington.
Other optometrist in Bellevue
- Charles ClaytonBellevue$195K
- Kristi KadingBellevue$9K
- Jing WickenburgBellevue$7K
- Joshlene SandhuBellevue$5K
- David KadingKirkland$397K
- Peter BergenskeOtis Orchards$355K
- Casey ClaypoolSpokane Valley$323K
- Rajiv PatelVancouver$118K
- Alan ChousTacoma$115K
- Roya HabibiSeattle$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.